Skip to main content

Advertisement

SpringerLink
Log in

Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients

  • Research Article
  • Published:
Tumor Biology

Abstract

The most important cytotoxic drug namely, cyclophosphamide used in breast cancer along with epirubicin and 5-fluorouracil, is transported by ABCC transporters and detoxified by glutathione S-transferases (GSTs). The activities of these enzymes and transporters may vary in different population due to the presence of genetic polymorphisms. This study was aimed to evaluate the effects of GSTP1rs1695 and ABCC4rs9561778 polymorphisms on the response and toxicities produced by chemotherapy used in the treatment of Bangladeshi breast cancer patients. A total of 200 and 56 patients with invasive breast cancers were recruited from different public and private hospitals of Bangladesh of which 117 patients received neoadjuvant chemotherapy to examine the response as well as the toxicity, and another 139 patients received adjuvant chemotherapy to evaluate only the toxicity. Genetic polymorphisms of the mentioned genes were detected by using Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR RFLP). Patients carrying AG and AG plus GG genotype of GSTP1rs1695 were more likely to have a good response, whereas no association of ABCC4rs9561778 was found with the chemotherapy response. Patients carrying GT and GT plus TT genotypes of ABCC4rs9561778 were found to be associated with anemia, neutropenia, leukopenia, and gastrointestinal toxicities when compared with GG genotype whereas no association was found with thrombocytopenia. GSTP1rs1695 was not associated with any type of toxicities investigated. Our result indicates that GSTP1rs1695 polymorphism was strongly associated with the response of chemotherapy, whereas ABCC4rs9561778 polymorphism was significantly related with chemotherapy-induced toxicities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase. 11th ed. Lyon: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Accessed 10 February 2014.

    Google Scholar 

  2. American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society. 2014. http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed 10 February 2014.

  3. Story HL, Love RR, Salim R, Roberto AJ, Krieger JL, Ginsburg OM. Improving outcomes from breast cancer in a low-income country: lessons from Bangladesh. Int J Breast Cancer. 2012;2012:423562.

    Article  CAS  PubMed  Google Scholar 

  4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.

    Article  CAS  PubMed  Google Scholar 

  5. Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, et al. Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res. 2010;16(24):6169–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Shigematsu H, Kadoya T, Masumoto N, Sasada T, Emi A, Ohara M, et al. The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial. Clin Breast Cancer. 2014. doi:10.1016/j.

  7. Zurrida S, Veronesi U. Milestones in breast cancer treatment. Breast J. 2015;21(1):3–12.

    Article  CAS  PubMed  Google Scholar 

  8. Jamieson D, Lee J, Cresti N, Jackson R, Griffin M, Sludden J, et al. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. Cancer Chemother Pharmacol. 2014;74(4):667–74.

    Article  CAS  PubMed  Google Scholar 

  9. Pinto N, Ludeman SM, Dolan ME. Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics. 2009;10(12):1897–903.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Afsar NA, Haenisch S, Mateen A, Usman A, Ufer M, Ahmed KZ, et al. Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy. Basic Clin Pharmacol Toxicol. 2010;107(1):570–6.

    Article  CAS  PubMed  Google Scholar 

  11. Ji M, Tang J, Zhao J, Xu B, Qin J, Lu J. Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biol Ther. 2012;13(5):264–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Low SK, Kiyotani K, Mushiroda T, Daigo Y, Nakamura Y, Zembutsu H. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet. 2009;54(10):564–71.

    Article  CAS  PubMed  Google Scholar 

  13. Islam MS, Ahmed MU, Sayeed MS, Maruf AA, Mostofa AG, Hussain SM, et al. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin Chim Acta. 2013;416:11–9.

    Article  CAS  PubMed  Google Scholar 

  14. Reich D, Thangaraj K, Patterson N, Price AL, Singh L. Reconstructing Indian population history. Nature. 2009;461(7263):489–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mehra NK. Defining genetic architecture of the populations in the Indian subcontinent: impact of human leukocyte antigen diversity studies. Indian J Hum Genet. 2010;16(3):105–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS 2009.

  17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  PubMed  Google Scholar 

  18. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. Chicago: Springer; 2010.

    Google Scholar 

  19. Islam MS, Mostofa AG, Ahmed MU, Bin Sayeed MS, Hassan MR, Hasnat A. Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population. Tumour Biol. 2014;35(2):1671–8.

    Article  CAS  PubMed  Google Scholar 

  20. Mostaid MS, Ahmed MU, Islam MS, Bin Sayeed MS, Hasnat A. Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population. Tumour Biol. 2014;35(10):10309–17.

    Article  CAS  PubMed  Google Scholar 

  21. Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011;63(2):437–59.

    Article  CAS  PubMed  Google Scholar 

  22. Tulsyan S, Chaturvedi P, Agarwal G, Lal P, Agrawal S, Mittal RD, et al. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach. Mol Diagn Ther. 2013;17(6):371–9.

    Article  CAS  PubMed  Google Scholar 

  23. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet. 2001;2:9–39.

    Article  CAS  PubMed  Google Scholar 

  24. Moyer AM, Salavaggione OE, Wu TY, Moon I, Eckloff BW, Hildebrandt MA, et al. Glutathione S-transferase P1: gene sequence variation and functional genomics studies. Cancer Res. 2008;68(12):4791–801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case–control study. Blood. 2000;95(4):1222–8.

    CAS  PubMed  Google Scholar 

  26. Yang G, Shu XO, Ruan ZX, et al. Genetic polymorphisms in glutathione-S-transferase genes (GSTM1, GSTT1, GSTP1) and survival after chemotherapy for invasive breast carcinoma. Cancer. 2005;103(1):52–8.

    Article  CAS  PubMed  Google Scholar 

  27. Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res. 2000;60(20):5621–4.

    CAS  PubMed  Google Scholar 

  28. Hohaus S, Di Ruscio A, Di Febo A, et al. Glutathione S-transferase P1 genotype and prognosis in Hodgkin’s lymphoma. Clin Cancer Res. 2005;11(6):2175–9.

    Article  CAS  PubMed  Google Scholar 

  29. Dasgupta RK, Adamson PJ, Davies FE, et al. Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood. 2003;102(7):2345–50.

    Article  CAS  PubMed  Google Scholar 

  30. Oliveira AL, Rodrigues FF, Santos RE, Aoki T, Rocha MN, Longui CA, et al. GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet Mol Res. 2010;9(2):1045–53.

    Article  CAS  PubMed  Google Scholar 

  31. Oliveira AL, Oliveira Rodrigues FF, Dos Santos RE, Rozenowicz RL, de Melo Barbosa M. GSTT1, GSTM1, and GSTP1 polymorphisms as a prognostic factor in women with breast cancer. Genet Mol Res. 2014;13(2):2521–30.

    Article  CAS  PubMed  Google Scholar 

  32. Zhang X, Li M, Wang H, Niu W, Wu Z, Shi G, et al. Polymorphism in glutathione S-transferase P1 (GSTP1) on the effect of epirubicin or doxorubicin chemotherapy among breast cancer. Afr J Pharm Pharmacol. 2013;7(2):54–7.

    Article  CAS  Google Scholar 

  33. Zhang BL, Sun T, Zhang BN, Zheng S, Lü N, Xu BH, et al. Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer. Chin Med J (Engl). 2011;124(2):199–204.

    CAS  Google Scholar 

  34. Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev. 2009;35(1):18–31.

    Article  CAS  PubMed  Google Scholar 

  35. Pankratz VS, Sun Z, Aakre J, Li Y, Johnson C, Garces YI, et al. Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer. J Thorac Oncol. 2011;6(9):1488–95.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Bai J, Lai L, Yeo HC, Goh BC, Tan TM. Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. Int J Biochem Cell Biol. 2004;36(2):247–57.

    Article  CAS  PubMed  Google Scholar 

  37. Zhao X, Guo Y, Yue W, Zhang L, Gu M, Wang Y. ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer. Onco Targets Ther. 2014;7:343–51.

    PubMed  PubMed Central  Google Scholar 

  38. Tanaka M, Takamatsu Y, Anan K, Ohno S, Nishimura R, Yamamoto Y, et al. Oral combination chemotherapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: a phase II study. Anticancer Drugs. 2010;21(4):453–8.

    Article  CAS  PubMed  Google Scholar 

  39. Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O’Regan R, et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014;32(22):2311–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors are thankful to all the teachers and staffs of the Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Bangladesh. The authors are also grateful to all the physicians, nurses, and staffs for their generous help and support during this study.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy and Pharmacology, Faculty of Pharmacy, University of Dhaka, Dhaka, 1000, Bangladesh

    Md. Siddiqul Islam, Salma Parvin, Maizbah Uddin Ahmed, Muhammad Shahdaat Bin Sayeed & Abul Hasnat

  2. Department of Pharmacy, Noakhali Science and Technology University, Sonapur, Noakhali, 3814, Bangladesh

    Mohammad Safiqul Islam

  3. Department of Pharmacy, University of Chittagong, Chittagong, 4331, Bangladesh

    Mir Muhammad Nasir Uddin

  4. Department of Oncology, Khwaja Younus Ali Medical College, Chowhali, Medical College Road, 6751, Bangladesh

    Syed Md Akram Hussain

Authors
  1. Md. Siddiqul Islam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohammad Safiqul Islam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salma Parvin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maizbah Uddin Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muhammad Shahdaat Bin Sayeed
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mir Muhammad Nasir Uddin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Syed Md Akram Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Abul Hasnat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Abul Hasnat.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Islam, M.S., Islam, M.S., Parvin, S. et al. Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients. Tumor Biol. 36, 5451–5457 (2015). https://doi.org/10.1007/s13277-015-3211-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-3211-y

Keyword

Search

Navigation